Saltar al contenido
Merck

In vitro susceptibilities of Mycoplasma putrefaciens field isolates.

Antimicrobial agents and chemotherapy (2007-07-20)
N T Antunes, M M Tavío, P Mercier, R D Ayling, W Al-Momani, P Assunção, R S Rosales, J B Poveda
RESUMEN

MICs were determined for 15 antimicrobial agents against 37 Mycoplasma putrefaciens isolates. The most effective antimicrobial drug classes were the fluoroquinolones, the tetracyclines, the lincosamide lincomycin, and the macrolides. The susceptibility profile of the isolates correlated with the geographic origin. This is the first report of decreased susceptibility to the macrolides, lincomycin, and the tetracyclines in M. putrefaciens strains.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Sigma-Aldrich
Nalidixic acid, ≥98%
Sigma-Aldrich
Enrofloxacin, ≥99.0%
Supelco
Norfloxacin, analytical standard, ≥98% (TLC)
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Supelco
Enrofloxacin, VETRANAL®, analytical standard
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Supelco
Norfloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.